Relationship between endothelial dysfunction and systemic inflammation in ulcerative colitis patients

Close metadata

Chronic systemic inflammation is associated with endothelial dysfunction in patients with ulcerative colitis (UC). The risk factors for endothelial damage include hypercholesterolemia, hyperhomocysteinemia, and increased levels of pro-inflammatory cytokines. The study of the reasons for endothelial dysfunction in patients with UC has diagnostic and prognostic value for curing patients and preventing cardiovascular pathologies.

OBJECTIVE

Establishing factors that influence the development of endothelial dysfunction in patients with UC.

MATERIAL AND METHODS

The study included 80 patients with UC. The lipid composition, homocysteine, E-selectin, VCAM-1, ICAM-1, C-reactive protein (CRP), TNF-α, and IL-6 levels were tested, and duplex scanning of extracranial vessels was carried out. The statistical indicators, including arithmetic mean and standard error of the mean; median, upper and lower quartiles; proportion and standard error of proportion; Mann—Whitney test; χ² with Yates correction; and Fisher’s exact test, two-tailed, were calculated using the Statistica 10 software package.

RESULTS

The blood lipid composition did not exceed normal values in patients with UC. The triglycerides and very low-density lipoprotein (VLDL) values positively correlated with the content of pro-inflammatory cytokines (IL-6 and TNF-α). The correlation of the latter with high-density lipoprotein levels was negative. The levels of E-selectin and ICAM-1 positively correlated with the content of TNF-α and CRP. A correlation between the homocysteine level and IL-6 and TNF-α cell adhesion molecules was not revealed. Co-morbid patients with UC and arterial hypertension had an increased thickness of the intima-media complex and higher levels of triglycerides, VLDL, CRP, and TNF-α.

CONCLUSION

In patients with ulcerative colitis, systemic inflammation initiates endothelial dysfunction, while hypercholesterolemia and hyperhomocysteinemia do not produce such an effect.

Keywords:

ulcerative colitis

systemic inflammation

lipid spectrum

cell adhesion molecules

intima-media complex

Authors:

Bikbavova G.R.

Omsk State Medical University

ORCID: 0000-0001-9252-9152

Livzan M.A.

Omsk State Medical University

ORCID: 0000-0002-6581-7017

Morova N.A.

Omsk State Medical University

ORCID: 0000-0003-0003-692X

Lisyutenko N.S.

Omsk State Medical University

ORCID: 0000-0003-4088-240X

Romanyuk A.E.

Omsk State Medical University

ORCID: 0000-0001-6308-4377

Tret’yakova T.V.

Regional Clinical Hospital

ORCID: 0000-0002-2663-0102

Received:

04.02.2024

Accepted:

27.04.2024

List of references:

Shelygin YuA, Ivashkin VT, Belousova EA, et al. Ulcerative colitis (K51), adults. Koloproktologia. 2023;22(1):10-44. (In Russ.). https://doi.org/10.33878/2073-7556-2023-22-1-10-44
Borowitz SM. The epidemiology of inflammatory bowel disease: Clues to pathogenesis? Frontiers in Pediatrics. 2023;10:1103713. https://doi.org/10.3389/fped.2022.1103713
Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570-1583. https://doi.org/10.1053/j.gastro.2020.12.031
Theofilis P, Sagris M, Oikonomou E, et al. Inflammatory mechanisms contributing to endothelial dysfunction. Biomedicines. 2021;9(7):781. https://doi.org/10.3390/biomedicines9070781
Xu S, Ilyas I, Little PJ, al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacological Reviews. 2021;73(3):924-967. https://doi.org/10.1124/pharmrev.120.000096
Gallo G, Volpe M, Savoia C. Endothelial dysfunction in hypertension: current concepts and clinical implications. Frontiers in Medicine. 2022;8:798958. https://doi.org/10.3389/fmed.2021.798958
Roumeliotis S, Mallamaci F, Zoccali C. Endothelial dysfunction in chronic kidney disease, from biology to clinical outcomes: a 2020 update. Journal of Clinical Medicine. 2020;9(8):2359. https://doi.org/10.3390/jcm9082359
Scioli MG, Storti G, D’Amico F, et al. Oxidative stress and new pathogenetic mechanisms in endothelial dysfunction: potential diagnostic biomarkers and therapeutic targets. Journal of Clinical Medicine. 2020;9(6):1995. https://doi.org/10.3390/jcm9061995
Wu H, Xu M, Hao H, et al. Endothelial dysfunction and arterial stiffness in patients with inflammatory bowel disease: a systematic review and meta-analysis. Journal of Clinical Medicine. 2022;11(11):31797. https://doi.org/10.3390/jcm11113179
Ray A, Maharana K C, Meenakshi S, Singh S. Endothelial dysfunction and its relation in different disorders: Recent update. Health Sciences Review. 2023:100084. https://doi.org/10.1016/j.hsr.2023.100084
Iazvennyi kolit. Klinicheskie rekomendatsii. 2022. Odobreno Nauchno-prakticheskim Sovetom Ministerstva zdravooxraneniya Rossijskoj Federacii. Accessed January 30, 2024. (In Russ.). https://cr.minzdrav.gov.ru/schema/193_1#doc_b
Ivanov AN, Grechikhin AA, Norkin IA, Puchinyan DM. Methods of endothelial dysfunction diagnosis. Regionarnoe krovoobrashhenie i mikrocirkuljacija. 2014;13(4):4-11. (In Russ.).
Martynov AI, Avetyak NG, Akatova EV, et al. Endothelial dysfunction and methods for its diagnostics. Rossijskij kardiologicheskij zhurnal. 2005;(4): 94-98. (In Russ.).
Biondi RB, Salmazo PS, Bazan SGZ, et al. Cardiovascular risk in individuals with inflammatory bowel disease. Clinical and Experimental Gastroenterology. 2020;13:107-113. https://doi.org/10.2147/CEG.S243478
Cibor D, Domagala-Rodacka R, Rodacki T, et al. Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications. World Journal of Gastroenterology. 2016;22(3):1067-1077. https://doi.org/10.3748/wjg.v22.i3.1067
Ferreira-Duarte M, Sousa JB, Diniz C, et al. Experimental and clinical evidence of endothelial dysfunction in inflammatory bowel disease. Current Pharmaceutical Design. 2020;26(30):3733-3747. https://doi.org/10.2174/1381612826666200701212414
Steyers CM 3rd, Miller FJ Jr. Endothelial dysfunction in chronic inflammatory diseases. International Journal of Molecular Sciences. 2014;15(7):11324-11349. https://doi.org/10.3390/ijms150711324
Arijs I, De Hertogh G, Machiels K, et al. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. The American Journal of Gastroenterology. 2011;106(4):748-761. https://doi.org/10.1038/ajg.2011.27
Chen H, Li W, Hu J, et al. Association of serum lipids with inflammatory bowel disease: a systematic review and meta-analysis. Frontiers in Medicine. 2023;10:1198988. https://doi.org/10.3389/fmed.2023.1198988
Lykowska-Szuber L, Rychter AM, Dudek M, et al. What links an increased cardiovascular risk and inflammatory bowel disease? a narrative review. Nutrients. 2021;13(8):2661. https://doi.org/10.3390/nu13082661
Bicbavova GR, Drapkina OM, Livzan MA, et al. Cardiovascular risk factors in patients with ulcerative colitis Terapevticheskii arkhiv. 2023;95(8):658-663. (In Russ.). https://doi.org/10.26442/00403660.2023.08.202338
Soh H, Im JP, Han K, et al. Crohn’s disease and ulcerative colitis are associated with different lipid profile disorders: a nationwide population-based study. Alimentary Pharmacology and Therapeutics. 2020;51(4):446-456. https://doi.org/10.1111/apt.15562
D’Ascenzo F, Bruno F, Iannaccone M, et al. Patients with inflammatory bowel disease are at increased risk of atherothrombotic disease: A systematic review with meta-analysis. International Journal of Cardiology. 2023;378: 96-104. https://doi.org/10.1016/j.ijcard.2023.02.042
Jaiswal V, Batra N, Dagar M, et al. Inflammatory bowel disease and associated cardiovascular disease outcomes: A systematic review. Medicine. 2023; 102(6):e32775. https://doi.org/10.1097/MD.0000000000032775
Olivera PA, Zuily S, Kotze PG, et al. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nature reviews. Gastroenterology and Hepatology. 2021;18(12): 857-873. https://doi.org/10.1038/s41575-021-00492-8
Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clinical Gastroenterology and Hepatology. 2008;6(1):41-45. https://doi.org/10.1016/j.cgh.2007.09.016
Li Z, Qiao L, Yun X, et al. Increased risk of ischemic heart disease and diabetes in inflammatory bowel disease. Zeitschrift fur Gastroenterologie. 2021; 59(2):117-124. https://doi.org/10.1055/a-1283-6966
Vavlukis M, Vavlukis A. Inflammation and endothelial dysfunction common mechanisms of inflammatory bowel diseases and cardiovascular disease. EC Gastroenterology and Digestive System. 2019;6(9):828-831.
Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA. Guideline on the management of blood cholesterol: a report of the American College of Cardiology. American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. https://doi.org/10.1161/CIR.0000000000000625
Wang A, Liu J, Li C, et al. Cumulative exposure to high-sensitivity C-reactive protein predicts the risk of cardiovascular disease. Journal of the American Heart Association. 2017;6(10):e005610. https://doi.org/10.1161/JAHA.117.005610
Stanojevic NB, Ivanović ZJ, Djurovic S, et al. Lack of association between low HDL-cholesterol and elevated circulating cellular adhesion molecules in normolipidemic CAD patients and healthy subjects. International Heart Journal. 2005;46(4):593-600. https://doi.org/10.1536/ihj.46.593

Close metadata